Filemon Sorillo Dela Cruz Jr. MD
Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology
Associate Attending, Pediatrics, Memorial Sloan Kettering Cancer Center
1275 York AvenueNew York, NY 10065
Overview of Dr. Dela Cruz
Dr. Filemon Dela Cruz is a pediatric oncologist and translational investigator at Memorial Sloan Kettering Cancer Center, where he serves as Associate Attending in the Department of Pediatrics. He completed his medical education at the University of California, Davis, his pediatrics residency at the University of California, San Francisco, and his fellowship in pediatric hematology/oncology at Columbia University Medical Center. His research focuses on developing and applying patient-derived xenograft (PDX) models integrated with genomic characterization, systems biology, and single-cell transcriptomics to identify and validate therapeutic strategies for high-risk pediatric solid tumors, particularly sarcomas. His preclinical work has directly informed the clinical development of several investigator-initiated trials, including agents targeting desmoplastic small round cell tumor, neuroblastoma, Wilms tumor, and HER2-expressing pediatric solid tumors. He serves as MPI of the NCI Pediatric Preclinical In Vivo Testing Program (PIVOT), Lead Investigator of the Pediatric Research in Oncology Xenografting Consortium (PROXC), Scientific Co-Chair of the Break Through Cancer Osteosarcoma Initiative, and Co-Chair of the Target Prioritization Committee of the Ewing Sarcoma Institute, and holds advisory roles with the CCDI Molecular Targets Platform, FNIH/COACH, and the Children's Oncology Group Bone Tumor and Sarcoma Biology Committees.
Education & Training
New York Presbyterian Hospital (Columbia Campus)Fellowship, Pediatric Hematology/Oncology, 2007 - 2010
University of California (San Francisco)Residency, Pediatrics, 2004 - 2007
University of California, Davis, School of MedicineClass of 2004
Reed CollegeBA, Biochemistry & Molecular Biology, 1994 - 1998
Certifications & Licensure
CA State Medical License 2006 - Present
FL State Medical License 2021 - Present
NJ State Medical License 2021 - 2027
NY State Medical License 2007 - 2027
American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- 11 citationsBromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor.Andrew D. Woods, Noah E. Berlow, Michael V. Ortiz, Filemon S. Dela Cruz, Armaan Siddiquee
Pediatric Blood & Cancer. 2021-10-24 - 9 citationsTranslational Strategies for Repotrectinib in Neuroblastoma.Tara O'Donohue, Glorymar Ibáñez, Diego F. Coutinho, Audrey Mauguen, Armaan Siddiquee
Molecular Cancer Therapeutics. 2021-09-04 - 87 citationsSTAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.Biniam Adane, Gabriela Alexe, Bo Kyung A. Seong, Diana Lu, Elizabeth Hwang
Cancer Cell. 2021-06-14
Grant Support
- The Development of Radiotherapeutic Paradigms for Desmoplastic Small Round Cell TumorHUNTER COLLEGE2026–2028
- Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid TumorsSLOAN-KETTERING INST CAN RESEARCH2021–2026
Professional Memberships
- Children's Oncology GroupMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
